AAD 2022 to Address Diversity, Health Equity, and Emerging Therapeutics
March 21st 2022Emerging research on therapeutics and practical approaches to managing a myriad of dermatological conditions, as well as a growing focus on diversity, equity, and inclusion will be explored at the 2022 American Academy of Dermatology (AAD) Annual Meeting, which will take place March 25-29, in Boston, Massachusetts.
Read More
Starting July 1, credit-reporting giants will remove certain medical debts; AstraZeneca’s Evusheld was shown to reduce the viral load of subvariants BA.1, BA1.1, and BA.2; about 4% of middle school students and 13% of high school students use some type of tobacco product, according to a report.
Read More
Dr Linda Stein Gold on What to Look Forward to at AAD 2022
March 21st 2022Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Watch
Investigating How Care Fragmentation May Affect Primary Care Redesign in Medicare
March 20th 2022On this episode of Managed Care Cast, Lori Timmins, PhD, and Eugene Rich, MD, discuss the findings of their interim analysis of data from the first 3 years of the Comprehensive Primary Care Plus Initiative, a large-scale effort of primary care redesign meant to improve care fragmentation among Medicare fee-for-service beneficiaries.
Listen
Examining Adjuvant Therapies in PD When Levodopa Wanes
March 19th 2022A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during OFF periods to see if one drug class had any benefit over another.
Read More
Increasing Rates of Women Receive Testing for Obstructive Sleep Apnea Diagnosis, According to Study
March 19th 2022A recent study found that older men with higher body mass index are more likely to receive a diagnosis of obstructive sleep apnea, but women are accounting for a growing number of new diagnoses.
Read More
Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL
March 19th 2022Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.
Read More
NFID Board Members: We Need More Accessible, Less Expensive RSV Testing
March 19th 2022William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.
Watch
Dupilumab Meaningfully Reduces Symptoms for Patients With EoE, Study Finds
March 19th 2022Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.
Read More
Why Measures Matter—and How to Inspire Cancer Practices to Use Them
March 19th 2022Quality measures are the lifeblood of practice transformation, but learning which ones make a difference—and how to use them to drive change—is as much an art as a science, according to 3 oncology care leaders who discussed the topic Friday at the 2022 Community Oncology Conference, presented by the Community Oncology Alliance.
Read More
Functional Impairment May Heighten Cardiometabolic Risk Among People Living With HIV
March 19th 2022Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.
Read More
FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC
March 19th 2022FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.
Read More
Dr Lalan Wilfong Addresses Influence, Future Use of HEOR in Community Oncology
March 18th 2022Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network, speaks on how use of health economics and outcomes research has benefitted patient care in the community oncology setting and where it can be further leveraged in the pursuit of value-based care.
Watch